Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Forest Laboratories, Inc. (NYSE:FRX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
909 Third Avenue
New York, NY 10022
Phone: (212) 421-7850
Fax: (212) 750-9152
Email: investor.relations@frx.com
Employees (last reported count): 2,826
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 500
Ownership
·Insider and 5%+ Owners: 27%
·Over the last 6 months:
 · 5 insider sells; 557.0K shares
  (1.1% of insider shares)
·Institutional: 87% (119% of float)
(968 institutions)
·Net Inst. Buying: 8.39M shares (+5.18%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Forest Laboratories, Inc. (Forest) develops, manufactures and sells both branded and generic forms of ethical drug products that require a physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter. The Company's most important U.S. products consist of branded ethical drug specialties marketed directly, or "detailed," to physicians by its Forest Pharmaceuticals, Forest Therapeutics and Forest Specialty sales forces. The Company's products include those developed by Forest and those acquired from other pharmaceutical companies and integrated into Forest's marketing and distribution systems. Principal products include Celexa, Forest's SSRI for the treatment of depression; the respiratory products Aerobid and Aerochamber; Tiazac, Forest's once-daily diltiazem for the treatment of hypertension and angina; and Infasurf, a lung surfactant for the treatment and prevention of respiratory distress syndrome in premature infants.
More from Market Guide: Expanded Business Description

Financial Summary
FRX develops, manufactures and sells both branded and generic forms of ethical drug products which require a physicians prescription, as well as non-prescription pharmaceutical products sold over-the counter. For the three months ended 6/30/01, revenues rose 35% to $359.1 million. Net income totaled $74 million, up from $28.3 million. Revenues reflect increased sales of Celexa and Tiazac. Net income also reflects improved plant utilization and product mix.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2001 Compensation
PayExer

Howard Solomon, 73
Chairman and CEO
$1.2M$147M
Kenneth Goodman, 53
Pres, COO
819K32M
John Eggers, 39
CFO, VP-Fin.
320K--  
Lawrence Olanoff, Ph.D., M.D., 49
Exec. VP-Scientific Affairs
712K13M
Elaine Hochberg, 44
Sr. VP of Marketing
524K--  
Dollar amounts are as of 31-Mar-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NYSE:FRXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 5-Sep-2000
$46.469
Recent Price$73.01 
52-Week High
on 18-July-2001
$82.33 
Beta0.63 
Daily Volume (3-month avg)1.37M
Daily Volume (10-day avg)1.52M
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+51.9%
52-Week Change
relative to S&P500
+103.8%
Share-Related Items
Market Capitalization$12.9B
Shares Outstanding177.3M
Float129.4M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 12-Jan-2001
Per-Share Data
Book Value (mrq)$7.36 
Earnings (ttm)$1.42 
Earnings (mrq)$0.40 
Sales (ttm)$7.06 
Cash (mrq)$2.85 
Valuation Ratios
Price/Book (mrq)9.92 
Price/Earnings (ttm)51.52 
Price/Sales (ttm)10.35 
Income Statements
Sales (ttm)$1.30B
EBITDA (ttm)$404.4M
Income available to common (ttm)$260.9M
Profitability
Profit Margin (ttm)20.1%
Operating Margin (ttm)27.9%
Fiscal Year
Fiscal Year EndsMar 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)19.35%
Return on Equity (ttm)22.76%
Financial Strength
Current Ratio (mrq)3.82 
Debt/Equity (mrq)0 
Total Cash (mrq)$505.1M
Short Interest
As of 8-Aug-2001
Shares Short2.85M
Percent of Float2.2%
Shares Short
(Prior Month)
2.58M
Short Ratio2.03 
Daily Volume1.41M
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.